Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Jointly modelling longitudinally measured urinary human chorionic gonadotrophin and early pregnancy outcomes.

Ashra NB, Marriott L, Johnson S, Abrams KR, Crowther MJ.

Sci Rep. 2020 Mar 12;10(1):4589. doi: 10.1038/s41598-020-61461-w.

2.

Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data.

Papanikos T, Thompson JR, Abrams KR, Städler N, Ciani O, Taylor R, Bujkiewicz S.

Stat Med. 2020 Apr 15;39(8):1103-1124. doi: 10.1002/sim.8465. Epub 2020 Jan 28.

3.

Mixed-effects models for health care longitudinal data with an informative visiting process: A Monte Carlo simulation study.

Gasparini A, Abrams KR, Barrett JK, Major RW, Sweeting MJ, Brunskill NJ, Crowther MJ.

Stat Neerl. 2020 Feb;74(1):5-23. doi: 10.1111/stan.12188. Epub 2019 Sep 5.

4.

Assessing causal treatment effect estimation when using large observational datasets.

John ER, Abrams KR, Brightling CE, Sheehan NA.

BMC Med Res Methodol. 2019 Nov 14;19(1):207. doi: 10.1186/s12874-019-0858-x.

5.

Impact of model misspecification in shared frailty survival models.

Gasparini A, Clements MS, Abrams KR, Crowther MJ.

Stat Med. 2019 Oct 15;38(23):4477-4502. doi: 10.1002/sim.8309. Epub 2019 Jul 21.

PMID:
31328285
6.

Risk of esophageal cancer in achalasia cardia: A meta-analysis.

Gillies CL, Farrukh A, Abrams KR, Mayberry JF.

JGH Open. 2019 Feb 8;3(3):196-200. doi: 10.1002/jgh3.12132. eCollection 2019 Jun.

7.

Bivariate network meta-analysis for surrogate endpoint evaluation.

Bujkiewicz S, Jackson D, Thompson JR, Turner RM, Städler N, Abrams KR, White IR.

Stat Med. 2019 Aug 15;38(18):3322-3341. doi: 10.1002/sim.8187. Epub 2019 May 26.

8.

Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.

Conrado DJ, Larkindale J, Berg A, Hill M, Burton J, Abrams KR, Abresch RT, Bronson A, Chapman D, Crowther M, Duong T, Gordish-Dressman H, Harnisch L, Henricson E, Kim S, McDonald CM, Schmidt S, Vong C, Wang X, Wong BL, Yong F, Romero K; Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC).

J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):441-455. doi: 10.1007/s10928-019-09642-7. Epub 2019 May 24.

PMID:
31127458
9.
10.

Can we estimate the length of stay of very preterm multiples?

Seaton SE, Draper ES, Abrams KR, Modi N, Manktelow BN; UK Neonatal Collaborative.

Arch Dis Child Fetal Neonatal Ed. 2019 Sep;104(5):F568-F570. doi: 10.1136/archdischild-2018-316321. Epub 2019 Feb 2. No abstract available.

PMID:
30711925
11.

Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer.

Tan SH, Abrams KR, Bujkiewicz S.

Med Decis Making. 2018 Oct;38(7):834-848. doi: 10.1177/0272989X18788537. Epub 2018 Aug 13.

12.

Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?

Latimer NR, White IR, Abrams KR, Siebert U.

Stat Methods Med Res. 2019 Aug;28(8):2475-2493. doi: 10.1177/0962280218780856. Epub 2018 Jun 25.

13.

Estimating neonatal length of stay for babies born very preterm.

Seaton SE, Barker L, Draper ES, Abrams KR, Modi N, Manktelow BN; UK Neonatal Collaborative.

Arch Dis Child Fetal Neonatal Ed. 2019 Mar;104(2):F182-F186. doi: 10.1136/archdischild-2017-314405. Epub 2018 Mar 27.

14.

Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal.

Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ.

Med Decis Making. 2018 Feb;38(2):200-211. doi: 10.1177/0272989X17725740. Epub 2017 Aug 19.

16.

What factors predict length of stay in a neonatal unit: a systematic review.

Seaton SE, Barker L, Jenkins D, Draper ES, Abrams KR, Manktelow BN.

BMJ Open. 2016 Oct 18;6(10):e010466. doi: 10.1136/bmjopen-2015-010466. Review.

17.

Modelling Neonatal Care Pathways for Babies Born Preterm: An Application of Multistate Modelling.

Seaton SE, Barker L, Draper ES, Abrams KR, Modi N, Manktelow BN; UK Neonatal Collaborative.

PLoS One. 2016 Oct 20;11(10):e0165202. doi: 10.1371/journal.pone.0165202. eCollection 2016.

18.

Analysis of urinary human chorionic gonadotrophin concentrations in normal and failing pregnancies using longitudinal, Cox proportional hazards and two-stage modelling.

Marriott L, Zinaman M, Abrams KR, Crowther MJ, Johnson S.

Ann Clin Biochem. 2017 Sep;54(5):548-557. doi: 10.1177/0004563216671339. Epub 2016 Oct 17.

PMID:
27629911
19.

Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX study).

Owen RK, Abrams KR, Mayne C, Slack M, Tincello DG.

Neurourol Urodyn. 2017 Apr;36(4):1201-1207. doi: 10.1002/nau.23095. Epub 2016 Aug 26.

PMID:
27564599
20.

NICE DSU Technical Support Document 16: Adjusting Survival Time Estimates in the Presence of Treatment Switching [Internet].

Latimer NR, Abrams KR.

London: National Institute for Health and Care Excellence (NICE); 2014 Jul.

21.

Accounting for heterogeneity in meta-analysis using a multiplicative model-an empirical study.

Mawdsley D, Higgins JP, Sutton AJ, Abrams KR.

Res Synth Methods. 2017 Mar;8(1):43-52. doi: 10.1002/jrsm.1216. Epub 2016 Jun 3.

PMID:
27259973
22.

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.

Latimer NR, Bell H, Abrams KR, Amonkar MM, Casey M.

Cancer Med. 2016 May;5(5):806-15. doi: 10.1002/cam4.643. Epub 2016 Jan 27.

23.

Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.

Nazir SA, McCann GP, Greenwood JP, Kunadian V, Khan JN, Mahmoud IZ, Blackman DJ, Been M, Abrams KR, Shipley L, Wilcox R, Adgey AA, Gershlick AH.

Eur Heart J. 2016 Jun 21;37(24):1910-9. doi: 10.1093/eurheartj/ehw136. Epub 2016 May 4.

24.

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.

Latimer NR, Abrams KR, Lambert PC, Morden JP, Crowther MJ.

Stat Methods Med Res. 2018 Mar;27(3):765-784. doi: 10.1177/0962280216642264. Epub 2016 Apr 25.

PMID:
27114326
25.

Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER).

Walker S, Asaria M, Manca A, Palmer S, Gale CP, Shah AD, Abrams KR, Crowther M, Timmis A, Hemingway H, Sculpher M.

Eur Heart J Qual Care Clin Outcomes. 2016 Jan 20;2(2):125-140.

26.

Joint longitudinal hurdle and time-to-event models: an application related to viral load and duration of the first treatment regimen in patients with HIV initiating therapy.

Brilleman SL, Crowther MJ, May MT, Gompels M, Abrams KR.

Stat Med. 2016 Sep 10;35(20):3583-94. doi: 10.1002/sim.6948. Epub 2016 Mar 29.

PMID:
27027882
27.

Using electronic health records to predict costs and outcomes in stable coronary artery disease.

Asaria M, Walker S, Palmer S, Gale CP, Shah AD, Abrams KR, Crowther M, Manca A, Timmis A, Hemingway H, Sculpher M.

Heart. 2016 May 15;102(10):755-62. doi: 10.1136/heartjnl-2015-308850. Epub 2016 Feb 10.

28.

Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity.

Owen RK, Abrams KR, Mayne C, Slack M, Tincello DG.

Neurourol Urodyn. 2017 Feb;36(2):426-431. doi: 10.1002/nau.22948. Epub 2016 Jan 12.

PMID:
26756171
29.

Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process.

Bujkiewicz S, Thompson JR, Riley RD, Abrams KR.

Stat Med. 2016 Mar 30;35(7):1063-89. doi: 10.1002/sim.6776. Epub 2015 Nov 3.

30.

Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification.

Crowther MJ, Andersson TM, Lambert PC, Abrams KR, Humphreys K.

Stat Med. 2016 Mar 30;35(7):1193-209. doi: 10.1002/sim.6779. Epub 2015 Oct 29.

31.

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints.

Bujkiewicz S, Thompson JR, Spata E, Abrams KR.

Stat Methods Med Res. 2017 Oct;26(5):2287-2318. doi: 10.1177/0962280215597260. Epub 2015 Aug 13.

32.

Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.

Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C, Swann RS.

Oncologist. 2015 Jul;20(7):798-805. doi: 10.1634/theoncologist.2014-0429. Epub 2015 Jun 3.

33.

Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.

Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL, Campbell MJ.

Stat Methods Med Res. 2017 Apr;26(2):724-751. doi: 10.1177/0962280214557578. Epub 2014 Nov 21.

PMID:
25416688
34.

A Comprehensive Assessment of Early Trial Evidence in Primary Breast Cancer: How Decisions Change Over Time.

Dequen P, Cooper NJ, Abrams KR.

Value Health. 2014 Nov;17(7):A652. doi: 10.1016/j.jval.2014.08.2372. Epub 2014 Oct 26. No abstract available.

35.

Evaluation of Methods for the Inclusion of Real World Evidence in Network Meta-Analysis - A Case Study in Multiple Sclerosis.

Jenkins D, Czachorowski M, Bujkiewicz S, Dequen P, Jonsson P, Abrams KR.

Value Health. 2014 Nov;17(7):A576. doi: 10.1016/j.jval.2014.08.1941. Epub 2014 Oct 26. No abstract available.

36.

Cost of Previously Treated Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin's Lymphoma (INHL) in the United Kingdom (UK).

Cognet M, Druais S, Gervais F, Gauthier A, Abrams KR.

Value Health. 2014 Nov;17(7):A549. doi: 10.1016/j.jval.2014.08.1787. Epub 2014 Oct 26. No abstract available.

37.

The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

Nazir SA, Khan JN, Mahmoud IZ, Greenwood JP, Blackman DJ, Kunadian V, Been M, Abrams KR, Wilcox R, Adgey AA, McCann GP, Gershlick AH.

Trials. 2014 Sep 25;15:371. doi: 10.1186/1745-6215-15-371.

38.
39.

Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds.

Nicholson KG, Abrams KR, Batham S, Medina MJ, Warren FC, Barer M, Bermingham A, Clark TW, Latimer N, Fraser M, Perera N, Rajakumar K, Zambon M.

Health Technol Assess. 2014 May;18(36):1-274, vii-viii. doi: 10.3310/hta18360.

40.

Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes.

Warren FC, Abrams KR, Sutton AJ.

Stat Med. 2014 Jun 30;33(14):2449-66. doi: 10.1002/sim.6131. Epub 2014 Mar 13.

PMID:
24623455
41.

Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.

Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL, Campbell MJ.

Med Decis Making. 2014 Apr;34(3):387-402. doi: 10.1177/0272989X13520192. Epub 2014 Jan 21.

PMID:
24449433
42.

Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis.

Bujkiewicz S, Thompson JR, Sutton AJ, Cooper NJ, Harrison MJ, Symmons DP, Abrams KR.

Value Health. 2014 Jan-Feb;17(1):109-15. doi: 10.1016/j.jval.2013.11.005.

43.

Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach.

Crowther MJ, Lambert PC, Abrams KR.

BMC Med Res Methodol. 2013 Dec 1;13:146. doi: 10.1186/1471-2288-13-146.

44.

Multivariate meta-analysis of mixed outcomes: a Bayesian approach.

Bujkiewicz S, Thompson JR, Sutton AJ, Cooper NJ, Harrison MJ, Symmons DP, Abrams KR.

Stat Med. 2013 Sep 30;32(22):3926-43. doi: 10.1002/sim.5831. Epub 2013 Apr 30. Review.

45.

Transparent interactive decision interrogator-reply to letter to the editor by Michael Coory.

Bujkiewicz S, Sutton AJ, Abrams KR, Cooper NJ, Spiegelhalter DJ.

Value Health. 2013 Jan-Feb;16(1):216-7. doi: 10.1016/j.jval.2012.10.014. No abstract available.

46.

Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study.

Tincello DG, Owen RK, Slack MC, Abrams KR.

BJOG. 2013 Jan;120(2):212-216. doi: 10.1111/1471-0528.12069. Epub 2012 Nov 27.

47.

Flexible parametric joint modelling of longitudinal and survival data.

Crowther MJ, Abrams KR, Lambert PC.

Stat Med. 2012 Dec 30;31(30):4456-71. doi: 10.1002/sim.5644. Epub 2012 Oct 4.

PMID:
23037571
48.

The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study.

Hinchliffe SR, Abrams KR, Lambert PC.

Cancer Epidemiol. 2013 Feb;37(1):11-9. doi: 10.1016/j.canep.2012.08.012. Epub 2012 Sep 20. Review.

PMID:
22999870
49.

A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: modelling study.

Khunti K, Gillies CL, Taub NA, Mostafa SA, Hiles SL, Abrams KR, Davies MJ.

Diabetes Res Clin Pract. 2012 Sep;97(3):505-13. doi: 10.1016/j.diabres.2012.03.009. Epub 2012 May 2.

PMID:
22554999
50.

Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event.

Warren FC, Abrams KR, Golder S, Sutton AJ.

BMC Med Res Methodol. 2012 May 3;12:64. doi: 10.1186/1471-2288-12-64.

Supplemental Content

Loading ...
Support Center